1 Min Read
July 17 (Reuters) - Axsome Therapeutics Inc
* Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.